GEN Exclusives

More »

GEN News Highlights

More »
Jan 9, 2007

InterMune Licenses Qualyst's Drug Discovery Technology

  • Intermune signed a multiyear license to use Qualyst's B-Clear® system for its drug discovery programs. 

    B-Clear offers research organizations the ability to generate physiologically-relevant data and enable decision making in areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug development challenges and enabling better prediction of bioavailability, pharmacokinetics, species-specific drug dosing, and candidate selection.

    The system is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance, and drug transport.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »